Glaukos Receives FDA Approval for iDose TR

Glaukos, a leading ophthalmic medical technology and pharmaceutical company, announced on Thursday the approval of their new drug application for iDose TR by the Food and Drug Administration (FDA). This groundbreaking treatment is designed to effectively reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

iDose TR distinguishes itself by delivering therapeutic levels of a proprietary formulation of travoprost directly into the eye over an extended period of time. This continuous delivery system ensures sustained and optimal treatment outcomes.

The FDA's approval of iDose TR is a result of the successful completion of two pivotal Phase 3 trials. These trials not only met their primary efficacy endpoints within three months but also demonstrated excellent tolerability and safety profiles for up to 12 months.

Glaukos is now preparing for the initial commercial launch of iDose TR, which is set to take place in the latter part of the first quarter of 2024.

About Glaukos: Glaukos is a leading ophthalmic medical technology and pharmaceutical company dedicated to developing and providing advanced solutions for eye diseases. With a focus on innovation and patient care, Glaukos strives to improve the lives of individuals suffering from ocular conditions.